23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Syndax Pharmaceuticals, Inc. › 2025-2026

Syndax Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Syndax Pharmaceuticals, Inc.’s Form 8-K, filed June 10, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Reported items
  • 258Asset managers, any item
  • 1,553Fund votes
  • June 10, 2026Meeting date

Results at a glance

Meeting of June 10, 2026: 6 items on Syndax Pharmaceuticals, Inc.’s Form 8-K, filed June 10, 2026: 6 passed (calculated).

Dissent

Significant dissent: 1 director (36.5% against).

Notable dissent: 1 other board item (43.2% against).

  • 4. Approval of the 2026 Plan 57% of votes cast Passed (calculated) Notable · 43.2% against

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Syndax Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Syndax Pharmaceuticals, Inc.

These tallies are Syndax Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Syndax Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 10, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Pierre Legault 37,294,888---- 21,467,9758,034,588 63%Passed (calculated)—
Elect Director: Michael A. Metzger 58,113,110---- 649,7538,034,588 99%Passed (calculated)—
2. Advisory vote on executive compensation 55,688,0392,985,35089,474 --8,034,588 95%Passed (calculated)—
3. Ratification of selection of independent registered public accounting firm 66,603,912162,94730,592 ---- 99.8%Passed (calculated)—
4. Approval of the 2026 Plan 33,333,26325,392,05137,549 --8,034,588 57%Passed (calculated)—
5. Approval of the 2026 ESPP 58,661,94174,04726,875 --8,034,588 99.9%Passed (calculated)—

Source: Syndax Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 10, 2026 — read the filing on EDGAR.

How asset managers voted at the Syndax Pharmaceuticals, Inc. 2025-2026 meeting

258 asset managers disclosed a vote on at least one Syndax Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Syndax Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Michael A. Metzger

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 58,113,110WITHHELD: 649,753
Details: description as filed, official tally, votes by 65 asset managers

Description as filed by funds: Election of Directors: Michael A. Metzger

Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Michael A. Metzger”): 58,113,110 for, 649,753 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 20,233,720 for, 67,015 withheld, 3 abstained.

FOR
FOR: 20,233,720ABSTAIN: 3WITHHOLD: 67,015
Largest asset managers voting on “Election of Directors: Michael A. Metzger” at Syndax Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,573,3660 30For
State Street2,679,6770 00For
Fidelity2,054,9090 00For
BlackRock2,043,0920 00For
TIAA1,440,6290 00For
Manager Directed Portfolios1,365,0570 00For
FRANKLIN STRATEGIC SERIES1,245,6150 00For
Charles Schwab718,9840 00For
BNY Mellon477,1960 00For
First Trust417,5870 00For
Columbia Threadneedle254,9700 00For
Delaware/Macquarie180,0000 00For
Invesco177,6890 00For
Equitable121,7260 054,760Mixed
QUANTITATIVE MASTER SERIES LLC137,3130 00For
JPMorgan122,6480 00For
Victory Capital111,5850 00For
SEI87,1060 00For
Tema ETF Trust84,6370 00For
Lincoln Financial77,5060 00For
ProShares71,0130 00For
AIG/SunAmerica58,3940 00For
Goldman Sachs53,2250 00For
SEI Exchange Traded Funds47,0790 00For
Northern Trust45,7030 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

Elect Director: Pierre Legault

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

63% Majority: yes · of votes cast

FOR 63%WITHHELD
FOR: 37,294,888WITHHELD: 21,467,975
Details: description as filed, official tally, votes by 65 asset managers

Description as filed by funds: Election of Directors: Pierre Legault

Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Pierre Legault”): 37,294,888 for, 21,467,975 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 63% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 14,847,771 for, 5,452,890 withheld, 77 abstained.

FORWITHHOLD
FOR: 14,847,771ABSTAIN: 77WITHHOLD: 5,452,890
Largest asset managers voting on “Election of Directors: Pierre Legault” at Syndax Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,535,1960 7738,097For
State Street5,3200 02,674,357Withhold
Fidelity2,054,2090 0700For
BlackRock2,043,0920 00For
TIAA1,440,6290 00For
Manager Directed Portfolios1,365,0570 00For
FRANKLIN STRATEGIC SERIES00 01,245,615Withhold
Charles Schwab718,9840 00For
BNY Mellon477,1960 00For
First Trust00 0417,587Withhold
Columbia Threadneedle254,9700 00For
Delaware/Macquarie00 0180,000Withhold
Invesco177,6890 00For
Equitable121,7260 054,760Mixed
QUANTITATIVE MASTER SERIES LLC137,3130 00For
JPMorgan122,6480 00For
Victory Capital00 0111,585Withhold
SEI00 087,106Withhold
Tema ETF Trust84,6370 00For
Lincoln Financial5,9640 071,542Mixed
ProShares00 071,013Withhold
AIG/SunAmerica00 058,394Withhold
Goldman Sachs53,2250 00For
SEI Exchange Traded Funds00 047,079Withhold
Northern Trust00 045,703Withhold

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

To approve the Syndax Pharmaceuticals, Inc. 2026 equity incentive plan.

47.2% Fund and manager reports combined; may count the same shares twice · no official result

FORAGAINST
Details: description as filed, votes by 66 asset managers

Description as filed by funds: TO APPROVE THE SYNDAX PHARMACEUTICALS, INC. 2026 EQUITY INCENTIVE PLAN.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 63 asset managers voting on “TO APPROVE THE SYNDAX PHARMACEUTICALS, INC. 2026 EQUITY INCENTIVE PLAN.” at Syndax Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,760,4043,812,965 00Mixed
State Street1,9052,677,772 00Against
Fidelity2,054,209700 00For
BlackRock2,043,0920 00For
TIAA01,440,629 00Against
Manager Directed Portfolios1,365,0570 00For
FRANKLIN STRATEGIC SERIES01,245,615 00Against
Charles Schwab718,9840 00For
BNY Mellon477,1960 00For
First Trust0417,587 00Against
Columbia Threadneedle0254,970 00Against
Delaware/Macquarie0180,000 00Against
Invesco0177,689 00Against
Equitable121,72654,760 00Mixed
QUANTITATIVE MASTER SERIES LLC137,3130 00For
JPMorgan122,6480 00For
Victory Capital0111,585 00Against
SEI87,1060 00For
Tema ETF Trust84,6370 00For
Lincoln Financial5,96471,542 00Mixed
ProShares071,013 00Against
AIG/SunAmerica058,394 00Against
Goldman Sachs53,2250 00For
SEI Exchange Traded Funds47,0790 00For
Northern Trust045,703 00Against

Fund voting reports, all 63 managers: 9,353,839 for, 10,943,103 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “TO APPROVE THE SYNDAX PHARMACEUTICALS, INC. 2026 EQUITY INCENTIVE PLAN.” at Syndax Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
APIS CAPITAL ADVISORS, LLC425,1080 00For
Vident Advisory, LLC9980 00For
Keel Point, LLC0905 00Against

Institutional-manager reports, all 3 managers: 426,106 for, 905 against.

To approve the Syndax Pharmaceuticals, Inc. 2026 employee stock purchase plan.

No official matchCOMPENSATION

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 65 asset managers

Description as filed by funds: TO APPROVE THE SYNDAX PHARMACEUTICALS, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN.

The 65 asset managers below reported 20,286,589 for, 12,255 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 20,286,589AGAINST: 12,255
Largest asset managers voting on “TO APPROVE THE SYNDAX PHARMACEUTICALS, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN.” at Syndax Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,573,3690 00For
State Street2,679,6770 00For
Fidelity2,054,9090 00For
BlackRock2,043,0920 00For
TIAA1,440,6290 00For
Manager Directed Portfolios1,365,0570 00For
FRANKLIN STRATEGIC SERIES1,245,6150 00For
Charles Schwab718,9840 00For
BNY Mellon477,1960 00For
First Trust417,5870 00For
Columbia Threadneedle254,9700 00For
Delaware/Macquarie180,0000 00For
Invesco177,6890 00For
Equitable176,4860 00For
QUANTITATIVE MASTER SERIES LLC137,3130 00For
JPMorgan122,6480 00For
Victory Capital111,5850 00For
SEI87,1060 00For
Tema ETF Trust84,6370 00For
Lincoln Financial77,5060 00For
ProShares71,0130 00For
AIG/SunAmerica58,3940 00For
Goldman Sachs53,2250 00For
SEI Exchange Traded Funds47,0790 00For
Northern Trust45,7030 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

Advisory vote on executive compensation

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 55,688,039AGAINST: 2,985,350

Prior year: 94.2% for (May 14, 2025 meeting) ▲ 0.7 pts

Details: description as filed, official tally, votes by 258 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement.

Syndax Pharmaceuticals, Inc.’s own tally for this item (“2. Advisory vote on executive compensation”): 55,688,039 for, 2,985,350 against, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 65 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Syndax Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,573,35613 00For
State Street2,678,5921,085 00For
Fidelity2,054,9090 00For
BlackRock2,043,0920 00For
TIAA1,440,6290 00For
Manager Directed Portfolios1,365,0570 00For
FRANKLIN STRATEGIC SERIES1,245,6150 00For
Charles Schwab718,9840 00For
BNY Mellon477,1960 00For
First Trust417,5870 00For
Columbia Threadneedle254,9700 00For
Delaware/Macquarie180,0000 00For
Invesco0177,689 00Against
Equitable176,4860 00For
QUANTITATIVE MASTER SERIES LLC137,3130 00For
JPMorgan122,6480 00For
Victory Capital111,5850 00For
SEI87,1060 00For
Tema ETF Trust84,6370 00For
Lincoln Financial77,5060 00For
ProShares71,0130 00For
AIG/SunAmerica58,3940 00For
Goldman Sachs53,2250 00For
SEI Exchange Traded Funds47,0790 00For
Northern Trust45,7030 00For

Fund voting reports, all 65 managers: 20,116,191 for, 178,787 against, 12,255 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 212 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Syndax Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
State Street4,379,67619,403 00For
BlackRock3,204,5987,821 00For
DEERFIELD MANAGEMENT COMPANY, L.P.2,701,7490 00For
Eversept Partners, LP2,341,4550 00For
KINGDON CAPITAL MANAGEMENT, L.L.C.2,333,5730 00For
Hood River Capital Management LLC2,268,4230 00For
FRANKLIN ADVISERS INC2,173,2300 00For
GEODE CAPITAL MANAGEMENT, LLC2,161,6100 00For
BNP Paribas Asset Management Holding S.A.01,726,437 00Against
Nuveen1,485,6880 00For
Aisling Capital Management LP1,316,8060 00For
Ensign Peak Advisors, Inc990,9690 00For
Candriam S.C.A.0925,332 00Against
Palo Alto Investors LP864,9860 00For
Two Sigma812,9650 00For
Newton Investment Management North America, LLC771,2460 00For
Vanguard720,9640 00For
Charles Schwab719,2930 00For
Northern Trust655,65711,912 00For
Trails Edge Capital Partners, LP640,8980 00For
ORBIMED ADVISORS LLC614,9510 00For
AQR609,9140 00For
MPM BioImpact LLC545,8690 00For
Woodline Partners LP496,2630 00For
APIS CAPITAL ADVISORS, LLC425,1080 00For

Institutional-manager reports, all 212 managers: 40,419,562 for, 3,450,848 against, 312 abstained, 209 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of selection of independent registered public accounting firm

Calculated outcomeAUDIT-RELATEDPassed (calculated)

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 66,603,912AGAINST: 162,947

Prior year: 99.9% for (May 14, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Syndax Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of selection of independent registered public accounting firm”): 66,603,912 for, 162,947 against, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 20,285,485 for, 106 against, 12,255 abstained.

FOR
FOR: 20,285,485AGAINST: 106ABSTAIN: 12,255
Largest asset managers voting on “TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIR” at Syndax Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,573,3690 00For
State Street2,679,571106 00For
Fidelity2,054,9090 00For
BlackRock2,043,0920 00For
TIAA1,440,6290 00For
Manager Directed Portfolios1,365,0570 00For
FRANKLIN STRATEGIC SERIES1,245,6150 00For
Charles Schwab718,9840 00For
BNY Mellon477,1960 00For
First Trust417,5870 00For
Columbia Threadneedle254,9700 00For
Delaware/Macquarie180,0000 00For
Invesco177,6890 00For
Equitable176,4860 00For
QUANTITATIVE MASTER SERIES LLC137,3130 00For
JPMorgan122,6480 00For
Victory Capital111,5850 00For
SEI87,1060 00For
Tema ETF Trust84,6370 00For
Lincoln Financial77,5060 00For
ProShares71,0130 00For
AIG/SunAmerica58,3940 00For
Goldman Sachs53,2250 00For
SEI Exchange Traded Funds47,0790 00For
Northern Trust45,7030 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Largest Syndax Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 88,610,027 shares outstanding at the time of that meeting.

Fund voting reports: top Syndax Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 6.29%
2State Street 3.02%
3Fidelity 2.32%
4BlackRock 2.31%
5TIAA 1.63%
6Manager Directed Portfolios 1.54%
7FRANKLIN STRATEGIC SERIES 1.41%
8Charles Schwab 0.81%
9BNY Mellon 0.54%
10First Trust 0.47%
Institutional-manager reports: top Syndax Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2025-2026
#Asset manager % of shares outstanding
1State Street 4.96%
2BlackRock 3.63%
3DEERFIELD MANAGEMENT COMPANY, L.P. 3.05%
4Eversept Partners, LP 2.64%
5KINGDON CAPITAL MANAGEMENT, L.L.C. 2.63%
6Hood River Capital Management LLC 2.56%
7FRANKLIN ADVISERS INC 2.45%
8GEODE CAPITAL MANAGEMENT, LLC 2.44%
9BNP Paribas Asset Management Holding S.A. 1.95%
10Nuveen 1.68%

Reported Syndax Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Syndax Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with Kynam Capital Management LP8,520,000 9.62%Proxy statement (DEF 14A), table as of March 30, 2026
Entities affiliated with BlackRock, Inc.6,744,049 7.61%Proxy statement (DEF 14A), table as of March 30, 2026
STATE STREET CORPORATION5,658,465 6.39%Schedule 13G, filed August 7, 2026
The Goldman Sachs Group5,581,828 6.30%Proxy statement (DEF 14A), table as of March 30, 2026
Vanguard Capital Management4,457,143 5.03%Schedule 13G, filed April 30, 2026
Point72 Asset Management, L.P.1,985,547 2.24%Schedule 13G, filed May 15, 2026
Michael A. Metzger1,969,574 2.22%Proxy statement (DEF 14A), table as of March 30, 2026
Luke J. Albrecht737,628 0.83%Proxy statement (DEF 14A), table as of March 30, 2026
Keith A. Goldan504,897 0.57%Proxy statement (DEF 14A), table as of March 30, 2026
Dennis G. Podlesak312,333 0.35%Proxy statement (DEF 14A), table as of March 30, 2026

Percentages above are of 88,610,027 shares outstanding, as reported by Syndax Pharmaceuticals, Inc. on its Form 10-Q dated April 27, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Syndax Pharmaceuticals, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 258 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,553 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Syndax Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Syndax Pharmaceuticals, Inc.’s 10-Q dated April 27, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Syndax Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Syndax Pharmaceuticals (SNDX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/syndax-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.